Alnylam expands hepatic infectious disease pipeline
Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the
Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the
As a company spokesperson for AdeptNature explained, the Premium Phytoceramides Capsules for Skin is an all-natural product that can help to soften, firm up and make skin look
Dixon Marketing is a highly respected leader in the military marketplace and will help KonaRed to bring its products to the military market. KonaRed’s CEO Shaun Roberts stated,
The partnership provides clinical and pathology laboratories that have adopted Cartagenia’s Bench for Oncology software platform for their genetic sequencing analysis and reporting workflow with the option to
To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR), the Université de
The portfolio includes leading brands built by strong levels of professional recommendations which have demonstrated excellent growth potential. The brands Lipo-Flavonoid®, Certain Dri®, Cystex®, Albolene, Absorbine Jr.®, and
If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy,
The study is the first time a targeted nanotherapeutic approach to microRNA replacement is being tested in patients with MPM. EnGeneIC’s EDV nanocells will be packaged with miR-16
AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel Breath Powered delivery technology. The FDA has raised questions regarding the human
The transaction, subject to regulatory approval and other customary closing conditions, is expected to close by the first quarter of 2015. Over the past seven years, KU has